RecruitingNCT07494305
LB-102 for a depressive episode in people with bipolarity
About this title
Read the official source — NCT07494305This study evaluates the safety and effectiveness of LB-102 for people with bipolarity.
Medication studyAges 18–65United States
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of LB-102 for people with bipolarity.
Who could participate?
This study is for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Bentonville and 25 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 23, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 320
- Sponsor
- LB Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07494305
- Official title
Show the full official title
A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Major Depressive Episodes Associated With Bipolar I Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Bentonville · Little Rock · Bellflower
23 more locations
- Culver City
- Garden Grove
- Lemon Grove
- Los Angeles
- Orange
- Riverside
- Torrance
- Doral
- Hollywood
- Miami Lakes
- West Palm Beach
- Atlanta
- Decatur
- Chicago
- Detroit
- St Louis
- Las Vegas
- New York
- Canton
- Philadelphia
- DeSoto
- Richardson
- Bellevue
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of LB-102 for people with bipolarity.
Who is behind this study?
The study sponsor is LB Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including LB-102.
Who can participate?
This study is for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
